Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis

@inproceedings{Wu2019ComparativeEA,
  title={Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis},
  author={Di Wu and Tiejun Chen and Han Jiang and Chongyang Duan and X Zhang and Yiguang Lin and Size Chen and Fenfang Wu},
  booktitle={Journal of oncology},
  year={2019}
}
This network meta-analysis addresses the need for evidence-based best-practice treatment regimens for HER2-positive breast cancer. We compared the relative efficacy and tolerability of currently available HER2-positive neoadjuvant immunotherapy regimens based on systematic searches of available randomized controlled trials (RCTs) data. Based on intention-to-treat principle, pathological complete response (pCR), overall serious adverse events (SAEs), and breast-conserving surgery (BCS) rate were… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 77 REFERENCES